Dear Colleagues,

On behalf of the University of Oslo, Oslo University Hospital — an accredited Comprehensive Cancer Centre, and Norway’s first innovation district Oslo Science City, in collaboration with the Joint Research Centre of the European Commission, we are excited to invite you to join us for the 13th International Symposium on Targeted Alpha Therapy. Please save the dates from May 13 through May 16, 2025 in Oslo, Norway at the Radisson Blu Plaza Hotel.

We build upon a fruitful tradition of a series of International Symposia on Targeted Alpha Therapy initiated by the Joint Research Centre in Karlsruhe in 1997, including the recent successful TAT 12 held in Cape Town in 2023.

Norway has a strong global position within targeted radionuclide therapy, including world leading research groups, commercial success stories like Xofigo, a range of new biotech startups, developed infrastructure for clinical trials, as well as pilot- and full-scale manufacturing and distribution competence.

Our endeavour is to present a state of the art in-person symposium with updates on recent developments across the spectrum of targeted alpha therapy. It also serves as a great opportunity to network with colleagues from around the world.

The international and local scientific committees of world-class experts have developed a multi-disciplinary program that will advance global exchange of education, research and patient care in this blossoming and rapidly developing field of cancer research and treatment. Don’t miss the opportunity to be a part of this game-changing meeting for TAT.

Oslo is the vibrant capital of Norway and among the fastest growing cities in Europe. Norway is also recognized as one of the most beautiful countries in the world offering various choices to experience the seas, mountains, glaciers, waterfalls and more. The conference venue is centrally located downtown Oslo with several cultural events in its close vicinity.

We look forward to your participation in TAT 13 and to welcoming you to Oslo!